Clinical Scorecard: Optimizing aztreonam/ceftazidime-avibactam therapy for difficult-to-treat Stenotrophomonas maltophilia pneumonia: roles of continuous infusion and therapeutic drug monitoring

At a Glance

Key Highlights

• A retrospective multinational cohort did not have sufficient power to establish differences among individual antimicrobial agents; its findings are hypothesis-generating.
• In one patient with S. maltophilia pulmonary infection, continuous infusion and TDM-guided dose adjustment achieved 100% target attainment for fT > MIC.
• A 10-patient CAZ/AVI case series reported target concentrations in all plasma assessments and 87.5% of infection-site assessments, but most patients had pathogens other than S. maltophilia.
• Ceftazidime TDM alone does not establish adequate exposure to avibactam or to the full aztreonam/CAZ/AVI combination.
• The source calls for prospective studies with patient-specific dosing, infusion methods, pathogen-specific MICs, component-level PK/PD targets, and clinical endpoints.

Guideline-Based Recommendations

Diagnosis

• The source does not provide diagnostic criteria for S. maltophilia pneumonia.
• Prospective investigations should include pathogen-specific MIC measurements.

Management

• The source does not establish a preferred antimicrobial regimen or demonstrate clinical superiority of aztreonam/CAZ/AVI.
• Continuous infusion with TDM-guided dose adjustment was feasible in the cited reports, but clinical benefit for S. maltophilia pneumonia remains unestablished.

Monitoring & Follow-up

• When evaluating aztreonam/CAZ/AVI exposure, account for the distinct pharmacodynamic targets of aztreonam, ceftazidime, and avibactam.
• Ceftazidime monitoring alone cannot verify adequate exposure to avibactam or the complete combination.

Risks

• The cited studies are limited by small sample sizes, and the 10-patient case series mainly involved pathogens other than S. maltophilia.
• In the case series, infection-site concentrations were inferred from published penetration ratios rather than measured directly; only two patients required TDM-based dose modification.
• The retrospective cohort did not report detailed patient-level dosing, infusion duration, dose adjustments, or TDM results, limiting assessment of antimicrobial exposure.

Patient & Prescribing Data

Evidence discussed includes critically ill patients with difficult-to-treat S. maltophilia pneumonia, one 11-year-old patient with cystic fibrosis and chronic S. maltophilia pulmonary infection, and a 10-patient CAZ/AVI case series mainly involving multidrug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.

In the 10-patient case series, CAZ/AVI was administered by continuous infusion after a loading dose at 5 g every 12 hours, with subsequent dose modifications based on ceftazidime TDM; the target was plasma and/or infection-site concentrations of at least 4–5 times the MIC. The source does not establish this regimen as effective for S. maltophilia pneumonia.

Clinical Best Practices

• Interpret antimicrobial outcome comparisons from the retrospective cohort as hypothesis-generating, not evidence of therapeutic superiority.
• Document antimicrobial doses, infusion durations, dose adjustments, and TDM results when assessing treatment exposure.
• Distinguish the fT > MIC targets for aztreonam and ceftazidime from avibactam's β-lactamase-inhibition concentration target.
• Design prospective studies to assess component-level PK/PD target attainment alongside clinical endpoints.

Related Resources & Content

• Mokrani et al. Treatment and outcomes of difficult-to-treat Stenotrophomonas maltophilia pneumonia in the intensive care unit: a multinational retrospective cohort study.
• Cowart and Ferguson. Case report of aztreonam and ceftazidime-avibactam treatment with continuous infusion and TDM in an 11-year-old patient with cystic fibrosis and S. maltophilia pulmonary infection.
• Goncette et al. Retrospective case series of continuous-infusion ceftazidime-avibactam with therapeutic drug monitoring.